Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Tisotumab vedotin shows promise in recurrent, metastatic cervical cancer

Key clinical point: Tisotumab vedotin shows encouraging activity and tolerability in heavily pretreated recurrent or metastatic cervical cancer.

Major finding: ORR in 55 cervical cancer patients was 35%, confirmed ORR was 22%.

Study details: A phase 1/2a expansion study of 55 patients

Disclosures: The innovaTV 201 trial is sponsored by Genmab A/S. Dr. Hong reported having no disclosures.

Citation:

Hong DS et al. SGO 2019, Abstract 19.